|Bid||85.60 x 100|
|Ask||85.61 x 400|
|Day's Range||85.56 - 85.73|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.25|
|Dividend & Yield||2.72 (3.18%)|
|1y Target Est||N/A|
In 1H17, Novartis's (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.
In 1H17, Novartis's (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis.
Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.